On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.
14 January 2015 | HIV i-Base
Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.
10 December 2014 | Science Daily
HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.
07 October 2014 | Science Daily
Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla . All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.
16 September 2014 | NATAP
Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.
10 July 2014 | International AIDS Society
The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.
01 July 2014 | HIV i-Base
A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.
10 March 2014 | HIV i-Base
European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.
16 December 2013 | Gilead press release
Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.
22 October 2013 | NATAP
A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.
19 September 2013 | NATAP